



Unusual infections and thrombotic events in Cushing's syndrome

Mattia Barbot¹ · Martina Lazzara² · Pierluigi Mazzeo¹ · Francesca Pecori Giraldi² 

Received: 7 September 2023 / Accepted: 20 August 2024
© The Author(s) 2024, corrected publication 2024

Abstract

The diagnosis of Cushing's syndrome requires a high degree of suspicion, especially in patients in whom typical features are overshadowed by other ailments. These include, among others, widespread opportunistic infections or sepsis and venous or arterial thromboembolism.

This Review will summarize available data on patients presenting with severe infections or thrombotic events and the best approach to diagnosis.

Keywords Cushing's syndrome · Infections · Opportunistic infections · Thrombosis · Thrombophilia

Introduction

Cushing's syndrome is a severe -although thankfully rare- endocrine disease. Its multifaceted presentation translates into signs and symptoms which may be easily recognized by the trained eye, e.g. moon facies, truncal obesity and muscle atrophy, and more unusual manifestations, such as susceptibility to opportunistic pathogens and thrombotic events. Thus, diagnosis of Cushing's syndrome often requires complex and expert work-up.

This Review will describe the current knowledge on Cushing's syndrome presenting with severe infection or acute thrombotic events and the best diagnostic approach for these patients.

An extensive MEDLINE search on the topic was performed independently by two authors (F.P.G. and M.B.), publications retrieved and read by all authors. The following search words were included: "Cushing's syndrome, thrombosis, thrombotic events, infection, mortality". Search terms were linked to Medical Subject Headings (MeSH) where available. Keywords and free words were used simultaneously. Additional articles were identified through

manual research and study of meta-analyses, review articles and cross references. Any discrepancy was resolved by discussion.

Hypercortisolism presenting with unusual infections

Pathophysiology

Glucocorticoids are known to affect the immune system at different levels [1, 2]. On the one side, leukocytosis with increased neutrophils and reduced lymphocyte counts are among the hallmarks of excess cortisol exposure [3–5]. Increased neutrophil counts in the blood stream are in part due to reduced adhesion and extravasation at infection sites, indicative of blunted acute immune response. Dampening of macrophage function, crucial to phagocytosis, and reduction of natural killer (NK) cells [6, 7] -a subset of lymphocytes involved in cellular cytotoxicity- further affect the first line immune response. Glucocorticoids also modulate proinflammatory and antiinflammatory cytokines resulting varied changes to cytokine microenvironment and immune cell function [1, 2].

The adaptative immune response relies primarily on lymphocytes, T-cells for cellular immunity and B-cells for antibody production. Patients with Cushing's syndrome present lower percentages of CD4+ lymphocytes -the so-called T-helper cells- and increased CD8+ cytotoxic lymphocytes [7], thus decreased CD4/CD8 ratio, a marker of immune

✉ Francesca Pecori Giraldi
francesca.pecorigiraldi@unimi.it

¹ Endocrinology Unit, Department of Medicine-DIMED, University Hospital of Padova, Padova, Italy

² Department of Clinical Sciences & Community Health, University of Milan, Via Commenda 19, Milano, Italy

activation. In clinical setting, low CD4+ counts have been described in a patient with ectopic ACTH secretion and multiple opportunistic infections [8].

In addition to these changes directly pertaining to the systemic immune response, patients with Cushing's syndrome may also present the low-grade inflammation common to individuals with obesity, diabetes and the metabolic syndrome [9].

Of note, ectopic Cushing's syndrome and adrenal cancer present increased immunosuppression related to malignancy itself, possibly exacerbated by chemotherapy and poor nutritional status in advanced metastatic disease [10–12].

Epidemiology

The chronic corticosteroid excess leads to immunocompromised status with reduction of defences toward opportunistic infections [2]. The prevalence of severe infections ranges from 20% in Cushing's disease to 50% in ectopic ACTH secretion [13, 14] (Table 1); overall, patients with Cushing's syndrome present a 5-fold higher risk for infection [15]. Ultimately, infections and sepsis represent the second cause of death among patients with Cushing's syndrome [15–23]. Indeed, Harvey Cushing himself reported the increased susceptibility to infection with high fatalities in his first series [24].

As mentioned above, patients with ectopic ACTH syndrome are more frequently affected by severe infections, often fatal [20] and this appears related to the degree of cortisol excess, usually more pronounced in ectopic disease [25]. In fact, the risk of infection is strongly correlated with the severity of hypercortisolism [20, 26, 27] across

etiologies of Cushing's syndrome and milder opportunistic infections, e.g. mucocutaneous fungal diseases, are probably frequent events. Indeed, a recent self-assessment survey revealed 3-fold higher prevalence of urinary tract infections and mycoses among patients with pituitary or benign adrenal Cushing's syndrome [28]. Conversely, a pediatric study reported cutaneous fungal infections in only 20% of children [27] thus, the true prevalence of mild infections remains to be established. Of note, infections may be overlooked in patients with Cushing's syndrome given that the classical acute response with fever and leukocytosis is blunted by cortisol excess itself [26].

Clinical course

Severe infections usually monopolize the clinical presentation and dictate management. The main species of opportunistic pathogens reported in patients with Cushing's syndrome are *Aspergillus fumigatus*, *Cryptococcus neoformans*, *Pneumocystis jirovecii*, *Nocardia asteroides* [2, 26, 29–48] (Supplementary Table 1). As with immunodeficient patients, these infections appear resistant to treatment, superimposed to other infections, widespread or in uncommon sites, and often fatal [8, 49]. Other, more common, agents -such as *mycobacterium tuberculosis*, cytomegalovirus and Herpes Zooster virus- may present an uncommonly severe course in patients with Cushing's syndrome. In fact, multiple mycobacterial abscesses [50] and disseminated Herpes Zooster [51] have been reported in patients with hypercortisolism.

Treatment of hypercortisolism, either medical and surgical, may be attempted to ameliorate the response to antibiotics and/or support therapy and, indeed, in several cases, led to resolution of the infection. Control of hypercortisolism is related to better outcomes and more rapid recovery from infections [26, 52].

Particular consideration should however be extended to patients with Cushing's syndrome and *pneumocystis jirovecii* (formerly *pneumocystis carinii*) pneumonia. In most patients with Cushing's syndrome reported so far [53–56] pneumonia developed after initiation of cortisol-lowering therapy. This timeline is in keeping with the so-called immune reconstitution inflammatory syndrome, i.e., an exaggerated inflammatory response to the fungus after reversal of immunosuppression.

Who should be screened

The diagnosis of Cushing's syndrome in patients presenting with infection requires a high degree of clinical suspicion by physicians unused to dealing with endocrine disorders. In fact, patients may attend the clinic for lung disease, skin

Table 1 Prevalence of severe infections in patients with active Cushing's syndrome

Study	Number of patients	Indicator
Papakokkinou 2020 [21]	830 person – year for 3 years prior to diagnosis (all CD)	sepsis: none
Dekkers 2013 [12]	343 patients (211 CD, 132 adrenal)	infections: HR ^a 2.6 (C.I. 1.1–6.4)
Broder 2015 [22]	1852 patients (all CD)	391 infections (21%)
Sarlis 2000 [16]	54 patients (all ectopic)	25 infections (46%)
Ilias 2005 [23]	90 patients (all ectopic)	46 infections (51%)
Ejaz 2011 [24]	43 patients (all ectopic)	10 infections (23%)
Toivanen 2021 [11]	60 patients (all ectopic)	33 infections (55%)
Mondin 2022 [25]	126 patients (all CD)	22 infections (17.5%)

CD: Cushing's disease; ^aHR: age-sex adjusted hazard ratio compared to general Danish population cohort; C.I. 95% confidence intervals

lesions, gastrointestinal perforation, central nervous system mass, among others. Only careful history taking and physical examination will lead to suspect Cushing's syndrome and avoid the pointless pursuit of other causes.

Patients presenting with opportunistic infections without a known underlying cause for immunosuppression should be evaluated for signs and symptoms of cortisol excess. Both severe systemic infections as well as chronic or recurring mild cutaneous infections should be considered suspicious for Cushing's syndrome.

As mentioned above, the severity of infection is correlated with the degree of cortisol excess, thus patients with paraneoplastic hypercortisolism -due either to ectopic ACTH secretion or malignant adrenal tumor- are most likely to be affected. In these patients, rapid onset of the disease and preponderance of catabolic effects may mask typical signs of Cushing's syndrome [2], such as obesity, facial plethora, and other features, e.g., hypokalemia, uncontrolled diabetes, may prompt the investigation [8, 43, 49]. Differential diagnosis encompasses some of the usual causes of non-neoplastic Cushing's syndrome, in particular long-standing alcoholism, as well as causes of immunodeficiency, i.e., HIV infection. The latter is of particular interest given the abnormal fat accumulation which has been reported to occur in patients treated with antiretroviral drugs, i.e., "HIV lipodistrophy" [57].

Diagnostic work-up

First line tests, i.e., urinary free cortisol, overnight suppression test, late-night salivary cortisol, should be used to screen for Cushing's syndrome, with some *caveats*. First, cortisol levels will inevitably be increased in critically ill patients, part of the physiological response to stress [58, 59]: On the other hand, a marked increase in serum cortisol -*per se* not used for the diagnosis of Cushing's syndrome- may be highly suggestive for endogenous hypercortisolism. Indeed, in most patients with infection reported in the literature [48, 60], cortisol levels were 3-to-4 fold higher than normal.

A second argument for caution is the concomitant use of corticosteroids for treatment of the infection. Urinary free cortisol may appear falsely elevated due to cross-reactivity with synthetic steroids, an issue which can be resolved using mass spectrometry [61] rather than immunometric assays on non-extracted urine [62].

Lastly, several antibiotics are CYP3A inducers, thus may accelerate hepatic dexamethasone clearance and lead to false positive responses to the overnight suppression test [63]. Should this appear to be the case, measurement of serum dexamethasone may prove useful [64].

The etiological diagnosis is sometimes redundant, as the primary lesion may be apparent at presentation in severe Cushing's syndrome due to adrenal or ectopic malignancies. Indeed, in severely ill patients, once the suspicion of Cushing's syndrome has been confirmed, treatment of hypercortisolism should be initiated promptly. Clinical judgement should indicate whether to proceed with the differential diagnosis, await recovery from infection or attempt adrenal imaging, should adrenalectomy appear a viable option. Differential diagnosis of ACTH-dependent Cushing's syndrome is best performed at expert centers [63].

Hypercortisolism presenting with thrombotic events

Pathophysiology

The first report on prothrombotic alterations in the coagulatory cascade in Cushing's syndrome dates back to the 1980 [65, 66]. Since then, a number of studies reported on hypercoagulability in endogenous hypercortisolism, the most consistent alterations being an increase in clotting factors, in particular factor VIII and von Willebrand factor (vWF), enhanced thrombin generation and reduced fibrinolysis [67–70]. Compensatory elevation of anticoagulants and fibrinolysis activators, such as protein C and plasminogen activator, [68, 69, 71, 72], has also been reported attesting to the complexity of hemostatic abnormalities in Cushing's syndrome. Biochemical testing reveals shortened aPTT [67], rapid clot formation [73] and prolonged clot lysis time [74].

In addition to hypercoagulability, patients with Cushing's syndrome also present other features of Virchow's triad, namely endothelial dysfunction and hemodynamic changes. Endothelial dysfunction has been documented in carotid [75] and coronary arteries [76], possibly due to features such as obesity, diabetes and hypertension [77] in addition to hypercortisolism *per se*. Reduction in blood flow may occur in bedridden patients with severe muscle atrophy or fractures or, in alternative, after surgery. Indeed, environmental triggers for thrombosis, such as reduced mobility and inflammation, proved decisive for the risk assessment of thromboembolic events in patients with Cushing's syndrome [78]. As for infections, patients with ectopic Cushing's syndrome and adrenal cancer present the highest risk of thrombotic events due to hypercoagulability induced by malignancy itself [79]. In these cases, thrombosis can affect multiple venous systems and is associated with lower survival [80].

Epidemiology

The risk of thrombotic events in patients with Cushing's syndrome has been quantified in several large retrospective studies [81–83]. Venous thromboembolism occurred in 4–10% of patients with active Cushing's syndrome [81, 82], regardless of the underlying etiology (Table 2). The standardized incidence ratio for thromboembolic events in the 3 years prior to diagnosis was estimated at 11.5 for patients with Cushing's disease [83]. Risk of thrombotic events is obviously higher in patients with malignant ectopic or adrenal cancer, given the known association of thromboembolism and neoplasia [84].

Venous thromboembolism may also occur after surgery, with percentages ranging from 3 to 12% in patients with Cushing's disease [81, 82]. Most events occurred within 2 months from transsphenoidal surgery although the standardized incidence ratio remained high even at long-term remission [83].

Arterial thrombotic events, such as myocardial infarction and stroke, represent the major cause of death in patients with Cushing's syndrome [23, 85]. Indeed, the hazard ratio for myocardial infarction and stroke is 2-to-3-fold than the

general population [15, 83, 86]. As with venous thromboembolism, the risk for these events abates but does not appear to entirely disappear after surgery [87].

No data is available on the prevalence of Cushing's syndrome among patients with venous or arterial thromboembolism. On the other hand, individuals with features of the metabolic syndrome, such as obesity, diabetes, hypertension, are known to present high risk for myocardial infarction and venous thromboembolism [88, 89]. Endogenous hypercortisolism has been shown to underly a small minority of these patients [90, 91] but concurrent thrombotic events may increase the likelihood of Cushing's syndrome.

Clinical course

Only scattered cases of Cushing's syndrome presenting with venous or arterial thrombosis have been reported. Both central, e.g. cavernous sinus [92], retina [93], intestinal [94] and peripheral venous thromboembolism as well as cardiac and peripheral arterial thrombosis [95, 96] were the cause of admission in these reports.

Thromboembolic complications during diagnostic work-up have been reported in a few patients after inferior petrosal sinus sampling [97, 98]; obviously, performing an endovascular procedure in patients at risk for thromboembolic events carries a higher degree of complications [99]. There have also been reports of disseminated intravascular coagulopathy (DIC) during the initial evaluation for hypercortisolism, usually in context with sepsis or multiple organ infection [100]. Management of the thromboembolic event is most often carried out prior to surgery; in some cases, adrenal steroid synthesis inhibitors were initiated concurrently with anticoagulants. Favourable evolution was reported in most cases, except for the rare patient with malignant tumor or widespread thrombosis.

As mentioned above, thromboembolic events are by far more frequent after surgery, usually within the first weeks from either adrenal or pituitary intervention [81]. All sites may be affected, in some cases even multiple locations in the same patient [101, 102], and possibly even recurring after initial successful treatment [103]. Guidelines for the prevention of postsurgical thromboembolic events are being discussed [104] as is the optimal treatment approach [63, 105, 106].

Who should be screened

As with patients presenting with infection, the diagnosis of Cushing's syndrome requires a high degree of suspicion in patients presenting with thromboembolism. Accurate medical history and thorough clinical evaluation are essential to evaluate known risk factors for thromboembolism, such as

Table 2 Prevalence of thrombotic events in patients with active Cushing's syndrome

Study	Number of patients	Indicator
Papakokkinou 2020 [21]	830 person – year for 3 year prior to diagnosis (all CD)	thromboembolism: SIR ^a 11.5 (C.I. 4.2–25) myocardial infarction: SIR ^a 4.4 (C.I. 1.2–11.4)
Suarez 2020 [80]	208 patients (168 CD, 14 adrenal, 8 ectopic)	12 thromboembolic events (5.7%)
Stuijver 2011 [81]	473 patients (353 CD, 120 adrenal)	17 thromboembolic events (3.6%)
Koutroumpi 2013 [90]	58 patients (43 CD, 13 adrenal, 2 ectopic)	4 thromboembolic events (6.8%)
Manetti 2010 [91]	40 patients (36 CD, 4 adrenal)	1 thromboembolic event (2.5%)
Dekkers 2013 [12]	343 patients (211 CD, 132 adrenal)	thromboembolism: HR ^b 8.4 (C.I. 3.0–23) myocardial infarction: HR ^b 2.2 (C.I. 0.5–8.9)
Toivanen 2021 [11]	60 patients (all ectopic)	5 thromboembolic events (8%)
Broder 2015 [22]	1852 patients (all CD)	203 cardiovascular disease/stroke events (11%)
Mondin 2023 [25]	126 patients (all CD)	23 thromboembolic events (18%) 9 cardiovascular events (7%)

CD: Cushing's disease ^aSIR: standardized incidence rate compared to general Swedish population; C.I. 95% confidence intervals; ^bHR: age-sex adjusted hazard ratio compared to general Danish population cohort

No adrenal malignancy was included in reported studies

malignancies, atherosclerotic disorders, drugs with thrombotic potential. Given the rareness of Cushing's syndrome and the higher prevalence of thrombotic events after surgery, evaluation for endogenous hypercortisolism is not mandated in patients presenting with thrombotic events alone. Clinical suspicion should rest on the presence of other, more specific, features of Cushing's syndrome [107].

Diagnostic work-up

Appropriate clinical judgment has to be used during the interpretation of tests for the diagnosis of Cushing's syndrome in patients presenting acute events such as deep vein thrombosis, pulmonary embolism, cerebral sinus thrombosis or mesenteric ischemia, all conditions reported in patients with pituitary or adrenal tumors. Mild elevations in midnight cortisol or urinary free cortisol may reflect the stress response rather than true endogenous hypercortisolism; the overnight suppression test, while less impaired by stress responses [62], may yield false positives in patients administered drugs accelerating dexamethasone metabolism [63]. In this context, estroprogestins –known prothrombotic drugs- are known to increase serum corticosteroid-binding globulin thus serum cortisol levels, and may impair the interpretation of the overnight suppression test [63]. On note, the suboptimal specificity of screening tests in patients presenting with features of the metabolic syndrome [108, 109], e.g., obesity, diabetes, hypertension –all known risk factors for thrombotic events-, mandates particular caution in the interpretation of test results.

Last, a word of caution on inferior petrosal sinus sampling (IPSS). As mentioned above, an endovascular procedure is inevitably associated with greater risk of complications in patients with endogenous hypercortisolism. Further, the current shortage of corticotropin-releasing hormone has led several centers to administer desmopressin as a stimulatory agent [110]. Desmopressin is used as an hemostatic agent in bleeding disorders and has been shown to stimulate the release of vWF and other endothelial markers in patients with Cushing's disease [111]. Thus, the risks of performing IPSS with desmopressin should be weighed against the risk of thrombotic events [112], especially in patients with high thrombotic risk profile.

Conclusions

Both infections and thrombosis are well known complications in Cushing's syndrome. However, the prevalence of hypercortisolism in these two conditions has never been assessed, a likely consequence of the rarity of endogenous cortisol excess. Uncommon infections without an

underlying immunosuppressive condition or apparent idiopathic thrombosis should raise the flag for the presence of cortisol excess and lead to targeted clinical evaluation.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40618-024-02454-8>.

Funding Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement - Open Access funding for this article was provided by Recordati Rare Diseases Italy S.r.l. The funder had no role in the preparation, review, or approval of the manuscript.”

Declarations

Conflict of interest All the authors declare that they have no conflicts of interest.

Ethical approval This article does not contain studies with human participants or animals performed by the authors.

Informed consent No informed consent required.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Hasenmajer V, Sbardella E, Sciarra F et al (2020) The Immune System in Cushing's syndrome. *Trends Endocrinol Metab* 31:655–669. <https://doi.org/10.1016/j.tem.2020.04.004>
2. Fareau GG (2007) R Vassilopoulou-Sellin Hypercortisolemia and infection. *Infect Dis Clin North Am* 21 639–657 <https://doi.org/10.1016/j.idc.2007.06.001> viii
3. Masri-Iraqi H, Robenshtok E, Tzvetov G et al (2014) Elevated white blood cell counts in Cushing's disease: association with hypercortisolism. *Pituitary* 17:436–440. <https://doi.org/10.1007/s11102-013-0522-0>
4. Paja M, Merlo I, Rodríguez-Soto J et al (2023) White blood cell count: a valuable tool for suspecting Cushing's syndrome. *J Endocrinol Invest* 46:141–149. <https://doi.org/10.1007/s40618-022-01892-6>
5. Deutsch V, Lerner-Geva L, Reches A et al (2007) Sustained leukocyte count during rising cortisol level. *Acta Haematol* 118:73–76. <https://doi.org/10.1159/000103216>
6. Masera RG, Staurengi A, Sartori ML, Angeli A (1999) Natural killer cell activity in the peripheral blood of patients with Cushing's syndrome. *Eur J Endocrinol* 140:299–306. <https://doi.org/10.1530/eje.0.1400299>

7. Kronfol Z, Starkman M, Scheingart DE et al (1996) Immune regulation in Cushing's syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones. *Psychoneuroendocrinology* 21:599–608. [https://doi.org/10.1016/s0306-4530\(96\)00021-2](https://doi.org/10.1016/s0306-4530(96)00021-2)
8. Bakker RC, Gallas PR, Romijn JA, Wiersinga WM (1998) Cushing's syndrome complicated by multiple opportunistic infections. *J Endocrinol Invest* 21:329–333. <https://doi.org/10.1007/BF03350337>
9. Ferrau F, Korbonits M (2015) Metabolic comorbidities in Cushing's syndrome. *Eur J Endocrinol* 173:M133–157. <https://doi.org/10.1530/EJE-15-0354>
10. Vento S, Cainelli F (2003) Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. *Lancet Oncol* 4:595–604. [https://doi.org/10.1016/s1470-2045\(03\)01218-x](https://doi.org/10.1016/s1470-2045(03)01218-x)
11. Puglisi S, Perotti P, Pia A et al (2018) Adrenocortical Carcinoma with Hypercortisolism. *Endocrinol Metab Clin North Am* 47:395–407. <https://doi.org/10.1016/j.ecl.2018.02.003>
12. Nagy-Mignotte H, Shestaeva O, Vignoud L et al (2014) Prognostic impact of paraneoplastic Cushing's syndrome in small-cell lung cancer. *J Thorac Oncol* 9:497–505. <https://doi.org/10.1097/JTO.0000000000000116>
13. Pivonello R, Isidori AM, De Martino MC et al (2016) Complications of Cushing's syndrome: state of the art. *Lancet Diabetes Endocrinol* 4:611–629. [https://doi.org/10.1016/S2213-8587\(16\)0086-3](https://doi.org/10.1016/S2213-8587(16)0086-3)
14. Toivanen S, Leijon H, Arola A et al (2021) Characteristics and outcomes of the Finnish ectopic ACTH syndrome cohort. *Endocrine* 74:387–395. <https://doi.org/10.1007/s12020-021-02768-0>
15. Dekkers OM, Horváth-Puhó E, Jørgensen JOL et al (2013) Multi-system morbidity and mortality in Cushing's syndrome: a cohort study. *J Clin Endocrinol Metab* 98:2277–2284. <https://doi.org/10.1210/jc.2012-3582>
16. Yaneva M, Kalinov K, Zacharieva S (2013) Mortality in Cushing's syndrome: data from 386 patients from a single tertiary referral center. *Eur J Endocrinol* 169:621–627. <https://doi.org/10.1530/EJE-13-0320>
17. Valassi E, Tabarin A, Brue T et al (2019) High mortality within 90 days of diagnosis in patients with Cushing's syndrome - results from the ERCUSYN registry. *Eur J Endocrinol*. <https://doi.org/10.1530/EJE-19-0464>
18. Papanicolaou DA, Mullen N, Kyrou I, Nieman LK (2002) Night-time salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. *J Clin Endocrinol Metab* 87:4515–4521. <https://doi.org/10.1210/jc.2002-020534>
19. Broder MS, Neary MP, Chang E et al (2015) Burden of illness, annual healthcare utilization, and costs associated with commercially insured patients with Cushing disease in the United States. *Endocr Pract* 21:77–86. <https://doi.org/10.4158/EP14126.OR>
20. Sarlis NJ, Chanock SJ, Nieman LK (2000) Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. *J Clin Endocrinol Metab* 85:42–47. <https://doi.org/10.1210/jcem.85.1.6294>
21. Ilias I, Torpy DJ, Pacak K et al (2005) Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. *J Clin Endocrinol Metab* 90:4955–4962. <https://doi.org/10.1210/jc.2004-2527>
22. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL et al (2011) Cushing syndrome secondary to ectopic adrenocorticotrophic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. *Cancer* 117:4381–4389. <https://doi.org/10.1002/cncr.26029>
23. Mondin A, Ceccato F, Voltan G et al (2023) Complications and mortality of Cushing's disease: report on data collected over a 20-year period at a referral centre. <https://doi.org/10.1007/s11102-023-01343-2>. Pituitary
24. Cushing H (1994) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932. *Obes Res* 2:486–508. <https://doi.org/10.1002/j.1550-8528.1994.tb00097.x>
25. Invitti C, Pecori Giralaldi F, de Martin M, Cavnagnini F (1999) Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the pathophysiology of the hypothalamic-pituitary-adrenal Axis. *J Clin Endocrinol Metab* 84:440–448. <https://doi.org/10.1210/jcem.84.2.5465>
26. Graham BS, Tucker WS (1984) Opportunistic infections in endogenous Cushing's syndrome. *Ann Intern Med* 101:334–338. <https://doi.org/10.7326/0003-4819-101-3-334>
27. Tatsi C, Boden R, Sinaii N et al (2018) Decreased lymphocytes and increased risk for infection are common in endogenous pediatric Cushing syndrome. *Pediatr Res* 83:431–437. <https://doi.org/10.1038/pr.2017.278>
28. Minnetti M, Hasenmajer V, Sbardella E et al (2022) Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool. *Eur J Endocrinol* 187:719–731. <https://doi.org/10.1530/EJE-22-0454>
29. Higgins TL, Calabrese LH, Sheeler LR (1982) Opportunistic infections in patients with ectopic ACTH-secreting tumors. *Cleve Clin Q* 49:43–49. <https://doi.org/10.3949/ccjm.49.1.43>
30. Naylor CD, Shkrum MJ, Edmonds MW, Cholod EJ (1988) Pulmonary aspergillosis and endophthalmitis: complications of Cushing's syndrome. *CMAJ* 138:719–720
31. Joubert M, Reznik Y, Verdon R (2007) Rescue bilateral adrenalectomy in paraneoplastic Cushing's syndrome with invasive aspergillus fumigatus infection. *Am J Med Sci* 334:497–498. <https://doi.org/10.1097/MAJ.0b013e3180a5e924>
32. Walsh TJ, Mendelsohn G (1981) Invasive aspergillosis complicating Cushing's syndrome. *Arch Intern Med* 141:1227–1228
33. Smith JM, Hampton JR, Webb RW (1979) Disseminated aspergillosis, Cushing's syndrome, and oat cell carcinoma of the lung. *Chest* 76:112–113. <https://doi.org/10.1378/chest.76.1.112>
34. Lutgers HL, Vergragt J, Dong P-V et al (2010) Severe hypercortisolism: a medical emergency requiring urgent intervention. *Crit Care Med* 38:1598–1601. <https://doi.org/10.1097/CCM.0b013e3181e47b7a>
35. Jonas C, Eucher P, Gustin T, Donckier JE (2013) Chronic necrotising aspergillosis mimicking ACTH-secreting tumour in a case of Cushing's disease. *Acta Clin Belg* 68:143–146. <https://doi.org/10.2143/ACB.3016>
36. Gondim J, Quidute AR, Maciel M et al (2003) Cushing's disease and sphenoidal aspergilloma. *Acta Radiol* 44:685–687. <https://doi.org/10.1080/02841850312331287849>
37. Bridenstine M, Kerr JM, Lillehei KO, Kleinschmidt-DeMasters BK (2013) Cushing's disease due to mixed pituitary adenoma-gangliocytoma of the posterior pituitary gland presenting with aspergillus sp. sinus infection. *Clin Neuropathol* 32:377–383. <https://doi.org/10.5414/NP300616>
38. Song BG, Lim MG, Bae JH et al (2021) Multiple opportunistic infections related to Hypercortisolemia due to Adrenocortical Carcinoma: a Case Report. *Infect Chemother* 53:797–801. <https://doi.org/10.3947/ic.2020.0205>
39. Takagi H, Matsumura Y, Fukuhara M et al (2022) Ectopic adrenocorticotrophic hormone-secreting carcinoid with solitary cryptococcosis in the lungs. *Cancer Rep (Hoboken)* 5:e1731. <https://doi.org/10.1002/cnr2.1731>
40. Kang C-I, Kim SH, Kim HB et al (2003) Disseminated cryptococcosis in a patient with pituitary Cushing's disease. *Korean J Intern Med* 18:199–201. <https://doi.org/10.3904/kjim.2003.18.3.199>
41. Thangakunam B, Christopher DJ, Kurian S et al (2008) Endogenous excess cortisol production and diabetes mellitus as predisposing factors for pulmonary cryptococcosis: a case report and

- literature review. *Lung India* 25:155–157. <https://doi.org/10.4103/0970-2113.45281>
42. Razavi B, O'Toole J, Schilling M, Razavi M (2000) Cryptococcal meningitis, an endocrine emergency? *Lancet* 355:1426. [https://doi.org/10.1016/S0140-6736\(00\)02142-5](https://doi.org/10.1016/S0140-6736(00)02142-5)
 43. Scheffel RS, Dora JM, Weinert LS et al (2010) Invasive fungal infections in endogenous Cushing's syndrome. *Infect Dis Rep* 2:e4. <https://doi.org/10.4081/idr.2010.e4>
 44. Sutton BJ, Parks GE, Manavi CK et al (2011) Cushing's syndrome and nocardiosis associated with a pulmonary carcinoid tumor: report of a case and review of the literature. *Diagn Cytopathol* 39:359–362. <https://doi.org/10.1002/dc.21428>
 45. Boscaro M, Fallo F, Sonino N (1994) Disseminated nocardiosis in a patient with Cushing's syndrome. *J Endocrinol Invest* 17:443–445. <https://doi.org/10.1007/BF03347735>
 46. Hays WB, Czosnowski Q (2022) Continuous etomidate for the management of Cushing's Syndrome Complicated by Pulmonary Nocardiosis. *J Pharm Pract* 35:1057–1059. <https://doi.org/10.1177/08971900211017487>
 47. Mylonas CC, Gomatou G, Asimakopoulou A et al (2019) Pulmonary nocardiosis associated with Cushing's disease: a case report. *Monaldi Arch Chest Dis* 89. <https://doi.org/10.4081/monaldi.2019.1130>
 48. Zhang D, Jiang Y, Lu L et al (2021) Cushing's syndrome with nocardiosis: a Case Report and a systematic review of the literature. *Front Endocrinol (Lausanne)* 12:640998. <https://doi.org/10.3389/fendo.2021.640998>
 49. Sieber SC, Dandurand R, Gelfman N et al (1989) Three opportunistic infections associated with ectopic corticotropin syndrome. *Arch Intern Med* 149:2589–2591
 50. Hill AT, Stewart PM, Hughes EA, Mcleod DT (1998) Cushing's disease and tuberculosis. *Respir Med* 92:604–606. [https://doi.org/10.1016/s0954-6111\(98\)90320-1](https://doi.org/10.1016/s0954-6111(98)90320-1)
 51. Yamauchi Y, Kameda H, Omori K et al (2021) Severe infection including disseminated herpes zoster triggered by subclinical Cushing's disease: a case report. *BMC Endocr Disord* 21:84. <https://doi.org/10.1186/s12902-021-00757-y>
 52. Chamuleau Sa, Corssmit J, Pereira EPM AM, et al (2008) A young woman with a severe bilateral pneumonia as the presenting sign of an adrenal carcinoma. *Neth J Med* 66:121–124
 53. van Halem K, Vrolijk L, Pereira AM, de Boer MGJ (2017) Characteristics and mortality of Pneumocystis Pneumonia in patients with Cushing's syndrome: a Plea for timely initiation of Chemoprophylaxis. *Open Forum Infect Dis* 4:ofx002. <https://doi.org/10.1093/ofid/ofx002>
 54. Lugat A, Lasolle H, François M et al (2023) Pneumocystis pneumonia in patients with Cushing's syndrome: a French multicenter retrospective study. *Ann Endocrinol (Paris)* 84:37–44. <https://doi.org/10.1016/j.ando.2022.09.020>
 55. Cristante J, Lefournier V, Sturm N et al (2019) Why we should still treat by neurosurgery patients with Cushing's disease and a normal or inconclusive pituitary MRI. *J Clin Endocrinol Metab.* <https://doi.org/10.1210/jc.2019-00333>
 56. Gabalec F, Zavrelová A, Havel E et al (2011) Pneumocystis pneumonia during medicamentous treatment of Cushing's syndrome—a description of two cases. *Acta Medica (Hradec Kralove)* 54:127–130. <https://doi.org/10.14712/18059694.2016.35>
 57. Miller KK, Daly PA, Sentochnik D et al (1998) Pseudo-cushing's syndrome in human immunodeficiency virus-infected patients. *Clin Infect Dis* 27:68–72. <https://doi.org/10.1086/514638>
 58. Peeters B, Langouche L, Van den Berghe G (2017) Adrenocortical Stress Response during the course of critical illness. *Compr Physiol* 8:283–298. <https://doi.org/10.1002/cphy.c170022>
 59. Ligtenberg JJ, Girbes AR, Beentjes JA et al (2001) Hormones in the critically ill patient: to intervene or not to intervene? *Intensive Care Med* 27:1567–1577. <https://doi.org/10.1007/s001340101050>
 60. Lu L, Zhao YY, Yang HB et al (2019) Cushing's disease with pulmonary Cryptococcus neoformans infection in a single center in Beijing, China: a retrospective study and literature review. *J Formos Med Assoc* 118:285–290. <https://doi.org/10.1016/j.jfma.2018.05.005>
 61. Ceccato F, Barbot M, Zilio M et al (2015) Screening tests for Cushing's syndrome: urinary free cortisol role measured by LC-MS/MS. *J Clin Endocrinol Metab* 100:3856–3861. <https://doi.org/10.1210/jc.2015-2507>
 62. Pecori Giralardi F, Ambrogio AG (2015) Variability in laboratory parameters used for management of Cushing's syndrome. *Endocrine* 50:580–589. <https://doi.org/10.1007/s12020-015-0676-9>
 63. Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing's disease: a guideline update. *Lancet Diabetes Endocrinol* 9:847–875. [https://doi.org/10.1016/S2213-8587\(21\)00235-7](https://doi.org/10.1016/S2213-8587(21)00235-7)
 64. Ceccato F, Artusi C, Barbot M et al (2020) Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. *J Endocrinol Invest* 43:1105–1113. <https://doi.org/10.1007/s40618-020-01197-6>
 65. Dal Bo Zanon R, Fornasiero L, Boscaro M et al (1982) Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. *Thromb Haemost* 47:116–117
 66. Small M, Lowe GD, Forbes CD, Thomson JA (1983) Thromboembolic complications in Cushing's syndrome. *Clin Endocrinol (Oxf)* 19:503–511. <https://doi.org/10.1111/j.1365-2265.1983.tb00025.x>
 67. Van Zaane B, Nur E, Squizzato A et al (2009) Hypercoagulable state in Cushing's syndrome: a systematic review. *J Clin Endocrinol Metab* 94:2743–2750. <https://doi.org/10.1210/jc.2009-0290>
 68. Patrassi GM, Sartori MT, Viero ML et al (1992) The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. *Blood Coagul Fibrinolysis* 3:789–793. <https://doi.org/10.1097/00001721-199212000-00013>
 69. Fatti LM, Bottasso B, Invitti C et al (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. *J Endocrinol Invest* 23:145–150. <https://doi.org/10.1007/BF03343697>
 70. Kastelan D, Dusek T, Kraljevic I, Aganovic I (2013) Hypercoagulable state in Cushing's syndrome is reversible following remission. *Clin Endocrinol (Oxf)* 78:102–106. <https://doi.org/10.1111/j.1365-2265.2012.04479.x>
 71. Koutroumpi S, Spiezia L, Albiger N et al (2014) Thrombin generation in Cushing's syndrome: do the conventional clotting indices tell the whole truth? *Pituitary* 17:68–75. <https://doi.org/10.1007/s11102-013-0467-3>
 72. Kastelan D, Dusek T, Kraljevic I et al (2009) Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. *Endocrine* 36:70–74. <https://doi.org/10.1007/s12020-009-9186-y>
 73. Coelho MCA, Vieira Neto L, Kasuki L et al (2014) Rotation thromboelastometry and the hypercoagulable state in Cushing's syndrome. *Clin Endocrinol (Oxf)* 81:657–664. <https://doi.org/10.1111/cen.12491>
 74. van der Pas R, de Bruin C, Leebeek FWG et al (2012) The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. *J Clin Endocrinol Metab* 97:1303–1310. <https://doi.org/10.1210/jc.2011-2753>
 75. Faggiano A, Pivonello R, Spiezia S et al (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year

- after disease remission. *J Clin Endocrinol Metab* 88:2527–2533. <https://doi.org/10.1210/jc.2002-021558>
76. Barahona M-J, Resmini E, Viladés D et al (2013) Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome. *J Clin Endocrinol Metab* 98:1093–1099. <https://doi.org/10.1210/jc.2012-3547>
 77. Albiger N, Testa RM, Almoto B et al (2006) Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. *Horm Metab Res* 38:405–410. <https://doi.org/10.1055/s-2006-944545>
 78. Zilio M, Mazzai L, Sartori MT et al (2016) A venous thromboembolism risk assessment model for patients with Cushing's syndrome. *Endocrine* 52:322–332. <https://doi.org/10.1007/s12020-015-0665-z>
 79. Khorana AA, Mackman N, Falanga A et al (2022) Cancer-associated venous thromboembolism. *Nat Rev Dis Primers* 8:11. <https://doi.org/10.1038/s41572-022-00336-y>
 80. Turbendian HK, Strong VE, Hsu M et al (2010) Adrenocortical carcinoma: the influence of large vessel extension. *Surgery* 148:1057–1064 discussion 1064. <https://doi.org/10.1016/j.surg.2010.09.024>
 81. Suarez MG, Stack M, Hinojosa-Amaya JM et al (2020) Hypercoagulability in Cushing Syndrome, Prevalence of thrombotic events: a large, Single-Center, Retrospective Study. *J Endocr Soc* 4:bvz033. <https://doi.org/10.1210/jendso/bvz033>
 82. Stuijver DJF, van Zaane B, Feelders RA et al (2011) Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. *J Clin Endocrinol Metab* 96:3525–3532. <https://doi.org/10.1210/jc.2011-1661>
 83. Papakokkinou E, Olsson DS, Chantzichristos D et al (2020) Excess morbidity persists in patients with Cushing's Disease during Long-Term Remission: A Swedish Nationwide Study. *J Clin Endocrinol Metab* 105:dga291. <https://doi.org/10.1210/clinem/dgaa291>
 84. Zwicker JJ, Furie BC, Furie B (2007) Cancer-associated thrombosis. *Crit Rev Oncol Hematol* 62:126–136. <https://doi.org/10.1016/j.critrevonc.2007.01.001>
 85. Ragnarsson O, Olsson DS, Papakokkinou E et al (2019) Overall and Disease-specific mortality in patients with Cushing Disease: A Swedish Nationwide Study. *J Clin Endocrinol Metab* 104:2375–2384. <https://doi.org/10.1210/jc.2018-02524>
 86. Clayton RN (2022) Cardiovascular complications of Cushing's syndrome: impact on morbidity and mortality. *J Neuroendocrinol* 34:e13175. <https://doi.org/10.1111/jne.13175>
 87. Kelsall A, Newell-Price J (2022) Cushing Mortality in Remission: not out of the Woods. *J Clin Endocrinol Metab* 107:e4232–e4233. <https://doi.org/10.1210/clinem/dgac341>
 88. Einarson TR, Acs A, Ludwig C, Panton UH (2018) Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. *Cardiovasc Diabetol* 17:83. <https://doi.org/10.1186/s12933-018-0728-6>
 89. De Paola L, Mehta A, Pana TA et al (2022) Body Mass Index and Mortality, recurrence and readmission after myocardial infarction: systematic review and Meta-analysis. *J Clin Med* 11:2581. <https://doi.org/10.3390/jcm11092581>
 90. Javorsky BR, Carroll TB, Tritos NA et al (2015) Discovery of Cushing's Syndrome after bariatric surgery: Multicenter Series of 16 patients. *Obes Surg* 25:2306–2313. <https://doi.org/10.1007/s11695-015-1681-z>
 91. Steffensen C, Pereira AM, Dekkers OM, Jørgensen JOL (2016) DIAGNOSIS OF ENDOCRINE DISEASE: prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. *Eur J Endocrinol* 175:R247–R253. <https://doi.org/10.1530/EJE-16-0434>
 92. Yoshimura S, Ago T, Kitazono T et al (2005) Cerebral sinus thrombosis in a patient with Cushing's syndrome. *J Neurol Neurosurg Psychiatry* 76:1182–1183. <https://doi.org/10.1136/jnnp.2004.057315>
 93. Kalaria TR, Chopra R, Ayuk J, Buch H (2021) Retinal vein occlusion as the presenting feature of Cushing's syndrome. *BMJ Case Rep* 14:e238204. <https://doi.org/10.1136/bcr-2020-238204>
 94. McDow AD, Gurung A, Poola R et al (2017) Portal vein thrombosis in the setting of newly diagnosed Cushing's syndrome. *J Investig Med High Impact Case Rep* 5:2324709617703672. <https://doi.org/10.1177/2324709617703672>
 95. Alexander V, Koshy M, Dasgupta R, Carey RA (2019) Arterial thrombosis as primary presentation of endogenous Cushing's syndrome. *BMJ Case Rep* 12. <https://doi.org/10.1136/bcr-2018-27491>
 96. Kim JH, Kim SY, Park JH (2014) Dilated cardiomyopathy with left ventricular thrombi as a presenting feature of Cushing disease. *Can J Cardiol* 30:1462e11–1462e13. <https://doi.org/10.1016/j.cjca.2014.06.018>
 97. Blevins LS, Clark RV, Owens DS (1998) Thromboembolic complications after inferior petrosal sinus sampling in patients with Cushing's syndrome. *Endocr Pract* 4:365–367. <https://doi.org/10.4158/EP.4.6.365>
 98. Obuobie K, Davies JS, Ogunko A, Scanlon MF (2000) Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease. *J Endocrinol Invest* 23:542–544. <https://doi.org/10.1007/BF03343772>
 99. Doppman JL (1999) There is no simple answer to a rare complication of inferior petrosal sinus sampling. *AJNR Am J Neuroradiol* 20:191–192
 100. Yoshihara A, Nishihama K, Inoue C et al (2022) Adrenocorticotrophic hormone-secreting pancreatic neuroendocrine carcinoma with multiple organ infections and widespread thrombosis: a case report. *World J Clin Cases* 10:5723–5731. <https://doi.org/10.12998/wjcc.v10.i17.5723>
 101. Contento MN, Rana S, Brutsaert E (2022) Multiple deep vein thromboses after curative surgery for Cushing Disease: a Case Presentation and Review. *AACE Clin Case Rep* 8:247–250. <https://doi.org/10.1016/j.aace.2022.08.003>
 102. Wijewickrama PSA, Ratnasamy V, Somasundaram NP et al (2021) A challenging case of Cushing's disease complicated with multiple thrombotic phenomena following trans-sphenoidal surgery: a case report. *BMC Endocr Disord* 21:29. <https://doi.org/10.1186/s12902-021-00701-0>
 103. Tong CV, Tee CK (2021) Recurrent cavernous sinus thrombosis: a rare complication of Cushing disease. *BMJ Case Rep* 14:e243786. <https://doi.org/10.1136/bcr-2021-243786>
 104. van Haalen FM, Kaya M, Pelsma ICM et al (2022) Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine conditions (Endo-ERN). *Orphanet J Rare Dis* 17:178. <https://doi.org/10.1186/s13023-022-02320-x>
 105. Boscaro M, Sonino N, Scarda A et al (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. *J Clin Endocrinol Metab* 87:3662–3666. <https://doi.org/10.1210/jcem.87.8.8703>
 106. Barbot M, Daidone V, Zilio M et al (2015) Perioperative Thromboprophylaxis in Cushing's disease: what we did and what we are doing? *Pituitary* 18:487–493. <https://doi.org/10.1007/s11102-014-0600-y>
 107. Braun LT, Vogel F, Zopp S et al (2022) Whom should we screen for Cushing Syndrome? The Endocrine Society Practice Guideline recommendations 2008 Revisited. *J Clin Endocrinol Metab* 107:e3723–e3730. <https://doi.org/10.1210/clinem/dgac379>

108. Baid SK, Rubino D, Sinaii N et al (2009) Specificity of screening tests for Cushing's syndrome in an overweight and obese population. *J Clin Endocrinol Metab* 94:3857–3864. <https://doi.org/10.1210/jc.2008-2766>
109. Pecori Giraldi F, Ambrogio AG, De Martin M et al (2007) Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. *J Clin Endocrinol Metab* 92:4123–4129. <https://doi.org/10.1210/jc.2007-0596>
110. Valizadeh M, Ahmadi AR, Ebadinejad A et al (2022) Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropin-releasing hormone in ACTH-dependent Cushing's syndrome: a systematic review and meta-analysis. *Rev Endocr Metab Disord* 23:881–892. <https://doi.org/10.1007/s11154-022-09723-y>
111. Giraldi FP, Ambrogio AG, Fatti LM et al (2011) Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease. *Br J Clin Pharmacol* 71:132–136. <https://doi.org/10.1111/j.1365-2125.2010.03812.x>
112. Pecori Giraldi F, Federici AB, Cavagnini F (2013) Caution during use of desmopressin in IPSS. *J Neurointerv Surg* 5:e27. <https://doi.org/10.1136/neurintsurg-2012-010580>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.